

General information about company	
Name of The Company	KILITCH DRUGS (INDIA) LIMITED
BSE Scrip Code	524500
NSE Symbol	KILITCH
MSE Symbol	NA
Date of Start of Financial Year	01-04-2023
Date of End of Financial Year	31-03-2024
Reporting Period	First half yearly
Date of Start of Reporting Period	01-04-2023
Date of End of Reporting Period	30-09-2023
Level of rounding to be used in disclosing related party transactions	Lakhs
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes

(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	

Related party transactions																					
												Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.									
Sr No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments				Notes
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	
1	Kilitch Drugs India Ltd	AAACK2917R	Mukund Mehta	AAAPM5972F	Managing Director	Remuneration			NA	27.5	0	0								Textual Information(1)	
2	Kilitch Drugs India Ltd	AAACK2917R	Bhavin Mehta	AFOPM2923F	Wholtime Director	Remuneration			NA	38.5	0	0								Textual Information(2)	
3	Kilitch Drugs India Ltd	AAACK2917R	Mira Mehta	AGJMP3218R	Wholtime Director	Remuneration			NA	11	0	0								Textual Information(3)	
4	Kilitch Drugs India Ltd	AAACK2917R	Sunil Jain	AHMPJ8872E	Chief Financial Officer	Remuneration			NA	6.06	0	0								Textual Information(4)	
5	Kilitch Drugs India Ltd	AAACK2917R	Pushpa Nyoupane	AQMPN8988L	Company Secretary	Remuneration			NA	2.34	0	0								Textual Information(5)	
6	Kilitch Drugs India Ltd	AAACK2917R	Hemang Jagdish Engineer	AAAPE0506B	Non Executive and Independent Director	Any other transaction	Sitting Fees		NA	0.25	0	0								Textual Information(6)	
7	Kilitch Drugs India Ltd	AAACK2917R	V. S. Rajan	AABPR7564D	Non Executive and Independent Director	Any other transaction	Sitting Fees		NA	0.03	0	0								Textual Information(7)	
8	Kilitch Drugs India Ltd	AAACK2917R	V. K. Murti	ADPTK1977E	Non Executive and Independent Director	Any other transaction	Sitting Fees		NA	0.25	0	0								Textual Information(8)	
9	Kilitch Drugs India Ltd	AAACK2917R	NBZ Healthcare LLP	AAKFN2329R	Few Directors are Partner	Purchase of goods or services		250	NA	58.46	0	58.46								Textual Information(9)	
10	Kilitch Drugs India Ltd	AAACK2917R	NBZ Healthcare LLP	AAKFN2329R	Few Directors are Partner	Advance		1200	NA	960.98	0	960.98				Advance	0	on demand	Unsecured	business activity	Textual Information(10)
11	Kilitch Drugs India Ltd	AAACK2917R	Kilitch Company Pharma Limited	AAACK9966A	Few Directors are Director	Advance		50	NA	0.77	0	0.77				Advance	0	on demand	Unsecured	business activity	Textual Information(11)
12	Kilitch Drugs India Ltd	AAACK2917R	Kilitch Estro Biotech PLC	ZZZZZ9999Z	Foreign Subsidiary	Sale of goods or services		250	NA	2.19	0	0									Textual Information(12)
13	Kilitch Drugs India Ltd	AAACK2917R	Kilitch Estro Biotech PLC	ZZZZZ9999Z	Foreign Subsidiary	Advance		250	NA	3.73	4260.03	4263.77				Loan	0.04	on demand	Unsecured	business activity	Textual Information(13)
14	Kilitch Drugs India Ltd	AAACK2917R	Monarchy Healthserve Pvt Ltd	AAECM9668H	Wholly Owned Subsidiary	Advance		100	NA	2.42	33.55	35.97				Advance	0	on demand	Unsecured	business activity	Textual Information(14)
Total																					

value of transaction during the reporting period	1114.48
--	---------

